ECLIPSE 1 Shows Rapid HDV Suppression: Nancy Reau, MDByHabiba Atta,Nancy Reau, MD, FAASLDNovember 16th 2026In the phase 3 ECLIPSE 1 trial, 44% on elebsiran plus tobevibart met the primary end point, with no treatment stops due to serious adverse events.